<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837823</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-1507</org_study_id>
    <secondary_id>HS#: 12-00741</secondary_id>
    <nct_id>NCT01837823</nct_id>
  </id_info>
  <brief_title>YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering</brief_title>
  <official_title>YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>InfraReDx (indirect)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well
      known that the reduction of cholesterol levels by statin therapy is associated with
      significant decreases in plaque burden. REVERSAL, ASTEROID, and more recently the SATURN II
      trial showed that in patients with CAD, lipid lowering with atorvastatin or rosuvastatin
      respectively reduced progression of coronary atherosclerosis, even causing plaque regression
      of some lesions. CAD clinical events are related to plaque instability due to lipid content
      and activity within the atherosclerotic plaque. The investigators recently completed the
      YELLOW I study, and identified that intensive statin therapy (rosuvastatin 40mg) was
      associated with a reduction in the amount of lipid in obstructive coronary plaques, as
      measured by near-infrared spectroscopy (NIRS). The YELLOW II study is designed to expand and
      build upon these results, and to provide mechanistic insights into the potential benefits of
      intensive statin therapy on atherosclerotic plaques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      YELLOW II is a single site study and will assess the regression of plaque lipid content and
      changes in plaque morphology from atherosclerotic lesions after high-dose statin therapy by
      utilizing NIRS, IVUS and optical coherency tomography (OCT) imaging modalities in the
      coronary arteries. We propose to image non-culprit coronary lesions using these modalities in
      patients with two or three diseased coronary vessels deemed to warrant intervention on
      clinical grounds. Thus, at the time of enrolment patients will undergo Percutaneous Coronary
      Intervention (PCI) of a non-study culprit lesion, and triple-modality imaging of the
      potential non-culprit ('YELLOW') lesion. If there is high baseline lipid content in the
      non-culprit YELLOW lesion (max 4mm LCBI &gt; 150), patients will be formally entered into this
      study. Following this, all enrolled subjects will receive high-dose lipid lowering therapy
      (rosuvastatin 40mg daily). The non-culprit YELLOW lesion will undergo staged intervention
      8-12 weeks following study enrolment and baseline imaging. At this time the YELLOW lesion
      will be reimaged to determine whether high-dose statin therapy caused a reduction in lipid
      content as assessed by NIRS, and other altered plaque morphology as assessed by OCT and IVUS.
      In addition, both at baseline and at the time of final non-culprit YELLOW lesion PCI, blood
      samples will be drawn during baseline and follow-up procedure to characterize reverse
      cholesterol transport by ability of patient HDL to accept cholesterol from cholesterol-laden
      (mouse J774) macrophage (cholesterol efflux) and the effect of patient HDL and apolipoprotein
      A1 on macrophage gene expression and migration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between Plaque Morphology and HDL Functionality</measure>
    <time_frame>baseline and 8-12 weeks</time_frame>
    <description>Correlation between the changes in plaque morphology composition by intravascular imaging with changes in HDL functionality. HDL functionality is measured by the Cholesterol Efflux Capacity (CEC). Plaque morphology is represented by the Fibrous Cap Thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP</measure>
    <time_frame>baseline and 8-12 weeks</time_frame>
    <description>Correlation between the change in plaque morphology composition by intravascular imaging with inflammatory cell activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>Maximum LCBI 4mm (ΔLCBI4mm max) of the non-culprit YELLOW lesion at baseline and 8-12 weeks thereafter.
LCBI4mm max : 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrous Cap Thickness (FCT) by OCT</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>ΔFibrous Cap Thickness measured by OCT at baseline and at 8-12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS Imaging Measures</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Correlation between ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in specific IVUS (ΔPlaque burden) imaging measures. Plaque burden is Plaque + Media divided by Total Plaque Area in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and Lipid Parameters</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in inflammatory and lipid parameters responses to patient-derived samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion LCBI</measure>
    <time_frame>at baseline and at 8-12 weeks</time_frame>
    <description>As related to other outcomes, change in LCBI measured across the entire lesion (rather than ΔLCBI4mm max). The LCBI Score, computed as the fraction of valid pixels within the scanned region that exceeded a LCP probability of 0.6 multiplied by 1000, summarized the amount of LCP in the entire scanned region of the coronary vessel on a 0-to-1000 scale .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCBI 4mm at Same Anatomical Site</measure>
    <time_frame>at baseline and at 8-12 weeks</time_frame>
    <description>As related to other outcomes, change in LCBI 4mm measured at the identical anatomical site at both time points, as defined by the LCBI4mm max site at baseline (rather than ΔLCBI4mm max).
LCBI4mm: 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atheroma Volume</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>Change in total atheroma volume (TAV) and lumen cross sectional area on OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Release</measure>
    <time_frame>within 24 hrs of PCI</time_frame>
    <description>Post procedure CK-MB, Troponin-I release at final YELLOW lesion PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation of baseline lipid parameters with baseline LCBI4mm max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque Morphology as Related to Haptoglobin</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>To relate changes in plaque lipid content and morphology to the patient haptoglobin genotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanism of Reverse Cholesterol Transport</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>To assess the mechanism of reverse cholesterol transport that arises with high-dose statin therapy, as related to changes in plaque lipid content and morphology, and systemic vascular inflammation. Reverse cholesterol transport (RCT) is a pathway by which accumulated cholesterol is transported from the vessel wall to the liver for excretion, thus preventing atherosclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Changes in Plaque Morphology</measure>
    <time_frame>baseline and at 8-12 weeks</time_frame>
    <description>Correlation of changes in plaque morphology by OCT, IVUS and NIRS with the perturbations in peripheral blood mononuclear cell transcriptome using microarray analysis.
data not collected for this measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>at 30 days</time_frame>
    <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>at 1 year</time_frame>
    <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 1 year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Obstructive Coronary Artery Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive rosuvastatin 40mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>All subjects will receive rosuvastatin 40mg/day for 8-12 weeks</description>
    <arm_group_label>rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age and willing to participate.

          -  Fluency in either English or Spanish.

          -  Stable patients who will undergo cardiac catheterization and PCI (intent to stent).

          -  Patient is willing to go on high-dose cholesterol lowering medication for the duration
             of the study

          -  Signed written Informed Consent.

          -  Women of childbearing potential must agree to be on an acceptable method of birth
             control/contraceptive such as barrier method (condoms/diaphragm); hormonal
             contraceptives (birth control pills, implants (Norplant) or injections
             (Depo-Provera)); Intrauterine Device.

          -  Proposed non-culprit YELLOW study lesion with max 4mm LCBI ≥ 150.

        Exclusion Criteria:

          -  Patients who have acute myocardial infarction (ST-segment elevation presentation, new
             Q waves or non-ST segment elevation with CK-MB &gt; 5 times above the upper normal (31.5
             ng/ml) within 72 hours).

          -  Patients who are in cardiogenic shock.

          -  Patients requiring coronary artery bypass graft surgery.

          -  Patients with platelet count &lt; 100,000 cell/mm3.

          -  Patients who have co-morbidity which reduces life expectancy to one year.

          -  Patients who are currently participating in another investigational drug/device study.

          -  Patients with liver disease.

          -  Patient with creatinine &gt; 2.0 mg/dL.

          -  Pregnant women and women of childbearing potential who intend to have children during
             the duration of the trial.

          -  Patients having undergone heart transplantation, or those that may undergo heart
             transplantation during the study period.

          -  Active autoimmune disease.

          -  Nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annapoorna Kini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Kovacic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <results_first_submitted>January 9, 2017</results_first_submitted>
  <results_first_submitted_qc>January 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annapoorna Kini</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Lipid</keyword>
  <keyword>Regression</keyword>
  <keyword>Plaque</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in July 2013, with enrollment from August 2013 to February 2015, 91 patients with multivessel CAD, who underwent percutaneous coronary intervention (PCI) for a culprit lesion followed by OCT and NIRS/IVUS imaging of an obstructive NCL were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin</title>
          <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin</title>
          <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior myocardial infarction (MI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior percutaneous coronary intervention (PCI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>atorvastatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>simvastatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>rosuvastatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pravastatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>fluvastatin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>none</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of coronary artery disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>the left anterior descending artery (LAD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>left circumflex artery (LCX)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>the right coronary artery (RCA)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Plaque Morphology and HDL Functionality</title>
        <description>Correlation between the changes in plaque morphology composition by intravascular imaging with changes in HDL functionality. HDL functionality is measured by the Cholesterol Efflux Capacity (CEC). Plaque morphology is represented by the Fibrous Cap Thickness.</description>
        <time_frame>baseline and 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Plaque Morphology and HDL Functionality</title>
          <description>Correlation between the changes in plaque morphology composition by intravascular imaging with changes in HDL functionality. HDL functionality is measured by the Cholesterol Efflux Capacity (CEC). Plaque morphology is represented by the Fibrous Cap Thickness.</description>
          <units>beta coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.07" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP</title>
        <description>Correlation between the change in plaque morphology composition by intravascular imaging with inflammatory cell activity.</description>
        <time_frame>baseline and 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP</title>
          <description>Correlation between the change in plaque morphology composition by intravascular imaging with inflammatory cell activity.</description>
          <units>beta coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-0.46" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)</title>
        <description>Maximum LCBI 4mm (ΔLCBI4mm max) of the non-culprit YELLOW lesion at baseline and 8-12 weeks thereafter.
LCBI4mm max : 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)</title>
          <description>Maximum LCBI 4mm (ΔLCBI4mm max) of the non-culprit YELLOW lesion at baseline and 8-12 weeks thereafter.
LCBI4mm max : 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
          <units>LCBI4mm max</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.6" spread="172.9"/>
                    <measurement group_id="O2" value="400.2" spread="180.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrous Cap Thickness (FCT) by OCT</title>
        <description>ΔFibrous Cap Thickness measured by OCT at baseline and at 8-12 weeks</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrous Cap Thickness (FCT) by OCT</title>
          <description>ΔFibrous Cap Thickness measured by OCT at baseline and at 8-12 weeks</description>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.9" spread="41.7"/>
                    <measurement group_id="O2" value="108.6" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Regression, Linear</method>
            <param_type>Pearson correlation coefficient</param_type>
            <param_value>-0.231</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVUS Imaging Measures</title>
        <description>Correlation between ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in specific IVUS (ΔPlaque burden) imaging measures. Plaque burden is Plaque + Media divided by Total Plaque Area in %.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>IVUS Imaging Measures</title>
          <description>Correlation between ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in specific IVUS (ΔPlaque burden) imaging measures. Plaque burden is Plaque + Media divided by Total Plaque Area in %.</description>
          <units>percent of plaque burden</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reference Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.75" spread="10.54"/>
                    <measurement group_id="O2" value="38.93" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Area Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.93" spread="7.07"/>
                    <measurement group_id="O2" value="75.79" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>for minimum lumen area site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Pearson correlation coefficient</method>
            <param_type>Pearson correlation coefficient</param_type>
            <param_value>0.074</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory and Lipid Parameters</title>
        <description>ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in inflammatory and lipid parameters responses to patient-derived samples.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory and Lipid Parameters</title>
          <description>ΔLCBI4mm max will be related to Δ values from baseline to 8-12 weeks thereafter in inflammatory and lipid parameters responses to patient-derived samples.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.3" spread="44.9"/>
                    <measurement group_id="O2" value="115.0" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="39.6"/>
                    <measurement group_id="O2" value="50.6" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="12.7"/>
                    <measurement group_id="O2" value="42.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.6" spread="111.8"/>
                    <measurement group_id="O2" value="107.8" spread="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="28.0"/>
                    <measurement group_id="O2" value="57.4" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo-AI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.1" spread="25.6"/>
                    <measurement group_id="O2" value="126.9" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hs-CRP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="55.0"/>
                    <measurement group_id="O2" value="27.0" spread="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion LCBI</title>
        <description>As related to other outcomes, change in LCBI measured across the entire lesion (rather than ΔLCBI4mm max). The LCBI Score, computed as the fraction of valid pixels within the scanned region that exceeded a LCP probability of 0.6 multiplied by 1000, summarized the amount of LCP in the entire scanned region of the coronary vessel on a 0-to-1000 scale .</description>
        <time_frame>at baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion LCBI</title>
          <description>As related to other outcomes, change in LCBI measured across the entire lesion (rather than ΔLCBI4mm max). The LCBI Score, computed as the fraction of valid pixels within the scanned region that exceeded a LCP probability of 0.6 multiplied by 1000, summarized the amount of LCP in the entire scanned region of the coronary vessel on a 0-to-1000 scale .</description>
          <units>LCBI4mm max</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.84" lower_limit="88.74" upper_limit="215.80"/>
                    <measurement group_id="O2" value="141.93" lower_limit="96.92" upper_limit="239.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LCBI 4mm at Same Anatomical Site</title>
        <description>As related to other outcomes, change in LCBI 4mm measured at the identical anatomical site at both time points, as defined by the LCBI4mm max site at baseline (rather than ΔLCBI4mm max).
LCBI4mm: 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
        <time_frame>at baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>LCBI 4mm at Same Anatomical Site</title>
          <description>As related to other outcomes, change in LCBI 4mm measured at the identical anatomical site at both time points, as defined by the LCBI4mm max site at baseline (rather than ΔLCBI4mm max).
LCBI4mm: 4-mm long segment with maximum lipid core burden index (LCBI), where the LCBI is calculated as the fraction of yellow pixels on a chemogram x 1000. Each pixel on the chemogram represents a probability of lipid presence in the given region; pixels are color-coded on a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow.</description>
          <units>LCBI4mm max</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.6" spread="172.9"/>
                    <measurement group_id="O2" value="383.2" spread="188.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atheroma Volume</title>
        <description>Change in total atheroma volume (TAV) and lumen cross sectional area on OCT.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atheroma Volume</title>
          <description>Change in total atheroma volume (TAV) and lumen cross sectional area on OCT.</description>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.3" spread="94.5"/>
                    <measurement group_id="O2" value="182.7" spread="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Release</title>
        <description>Post procedure CK-MB, Troponin-I release at final YELLOW lesion PCI.</description>
        <time_frame>within 24 hrs of PCI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Release</title>
          <description>Post procedure CK-MB, Troponin-I release at final YELLOW lesion PCI.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CK-MB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30." spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max</title>
        <description>Correlation of baseline lipid parameters with baseline LCBI4mm max</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max</title>
          <description>Correlation of baseline lipid parameters with baseline LCBI4mm max</description>
          <units>Beta coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.64" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plaque Morphology as Related to Haptoglobin</title>
        <description>To relate changes in plaque lipid content and morphology to the patient haptoglobin genotype.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <population>Only those participants with these genotypes were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Hp2-2</title>
            <description>Hp2-2 genotype</description>
          </group>
          <group group_id="O2">
            <title>Hp1-1/Hp 1-2</title>
            <description>Hp1-1 or Hp 102 genotype</description>
          </group>
        </group_list>
        <measure>
          <title>Plaque Morphology as Related to Haptoglobin</title>
          <description>To relate changes in plaque lipid content and morphology to the patient haptoglobin genotype.</description>
          <population>Only those participants with these genotypes were analyzed</population>
          <units>LCBI4mm max</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440.3" spread="171.8"/>
                    <measurement group_id="O2" value="403.0" spread="173.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 8-12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.0" spread="201.5"/>
                    <measurement group_id="O2" value="393.9" spread="168.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanism of Reverse Cholesterol Transport</title>
        <description>To assess the mechanism of reverse cholesterol transport that arises with high-dose statin therapy, as related to changes in plaque lipid content and morphology, and systemic vascular inflammation. Reverse cholesterol transport (RCT) is a pathway by which accumulated cholesterol is transported from the vessel wall to the liver for excretion, thus preventing atherosclerosis.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Prior to rosuvastatin therapy</description>
          </group>
          <group group_id="O2">
            <title>8-12 Weeks</title>
            <description>After 8-12 weeks of rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanism of Reverse Cholesterol Transport</title>
          <description>To assess the mechanism of reverse cholesterol transport that arises with high-dose statin therapy, as related to changes in plaque lipid content and morphology, and systemic vascular inflammation. Reverse cholesterol transport (RCT) is a pathway by which accumulated cholesterol is transported from the vessel wall to the liver for excretion, thus preventing atherosclerosis.</description>
          <units>percentage of cholesterol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.14"/>
                    <measurement group_id="O2" value="0.84" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Changes in Plaque Morphology</title>
        <description>Correlation of changes in plaque morphology by OCT, IVUS and NIRS with the perturbations in peripheral blood mononuclear cell transcriptome using microarray analysis.
data not collected for this measure.</description>
        <time_frame>baseline and at 8-12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Changes in Plaque Morphology</title>
          <description>Correlation of changes in plaque morphology by OCT, IVUS and NIRS with the perturbations in peripheral blood mononuclear cell transcriptome using microarray analysis.
data not collected for this measure.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MACE</title>
        <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days.</description>
        <time_frame>at 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MACE</title>
          <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MACE</title>
        <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 1 year.</description>
        <time_frame>at 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin</title>
            <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MACE</title>
          <description>Major Adverse Cardiac Events (MACE) defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 1 year.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin</title>
          <description>All subjects will receive rosuvastatin 40mg/day 8-12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Periprocedural complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Urgent revascularization</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Annapoorna Kini</name_or_title>
      <organization>Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-4181</phone>
      <email>annapoorna.kini@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

